Bio2 Technologies (Woburn, Mass.) has raised about $4.3 million as it continues with a clinical trial of its Vitrium resorbable orthopedic biomaterial for musculoskeletal surgery.
Bio2 had sought to raise $6.5 million in the funding round, according to a Form D filed Sept. 6 with the U.S. Securities and Exchange Commission.
Made of bioactive glass, Vitrium is porous, load-bearing, osteoconductive and bioactive, according to Bio2 Technologies. The idea is that it enables a surgeon to reconstruct bony anatomy without the clinical compromises that take place with the technologies presently available.
Bio2 Technologies in August announced the first implantation of an index patient in its randomized, multi-center, non-inferiority clinical trial. Dr. K. Brandon Strenge of the Orthopaedic Institute at Western Kentucky performed the procedure.
“I am very excited to be a part of this study evaluating a device that harnesses the patient’s own regenerative process to achieve a fusion without metal or plastic left behind, Strenge said. “I was particularly impressed with the ability of the spacer to rapidly absorb blood into its structure. This will likely become a compelling option for my patients.”
